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Time to try this warfarin 
alternative? 
Dabigatran appears to be as eff ective as warfarin in 
preventing stroke and thromboembolism in patients 
with atrial fi brillation—and is easier to use. 
.
PRACTICE CHANGER
Consider dabigatran, an oral anticoagulant 
that does not require monitoring, for the pre-
vention of stroke and thromboembolism in 
patients with atrial fi brillation.1
STRENGTH OF RECOMMENDATION
B: Based on a single well-done randomized 
controlled trial (RCT).
Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin 
in patients with atrial fi brillation. N Engl J Med. 2009;361:1139-1151.
ILLUSTRATIVE CASE
A 75-year-old man with persistent atrial fi bril-
lation and diabetes comes to your offi ce for 
a check of his international normalized ratio 
(INR). It has been hard to keep his INR within 
the normal range of 2 to 3 in recent months, 
and today is no different: The patient’s INR is 
1.7, although he insists he has been compli-
ant with his warfarin regimen and has had no 
change in diet or other medications. What oth-
er anticoagulation options can you offer him? 
Patients with atrial fi brillation have a 3% to 8% annual risk of stroke.2 Both adjusted-dose warfarin and antiplate-
let agents such as aspirin have been shown 
to be eff ective at reducing this risk, although 
warfarin is signifi cantly more eff ective.3 
Th ose who have atrial fi brillation and 
a previous history of thromboembolism or 
rheumatic mitral stenosis or more than one 
moderate risk factor (age ≥75 years, hyperten-
sion, heart failure, impaired left ventricular 
systolic function, or diabetes) have the highest 
stroke risk. Th e American College of Cardiol-
ogy/American Heart Association Task Force/
European Society of Cardiology (ACC/AHA/
ESC) 2006 guidelines for the management of 
atrial fi brillation recommend chronic antico-
agulation with an oral vitamin K antagonist, 
such as warfarin, for these high-risk patients.4 
Warfarin therapy is challenging 
We have all experienced the frustrations of 
maintaining our patients on warfarin at a ther-
apeutic INR; the average patient is within this 
range only about 67% of the time, although this 
varies dramatically from patient to patient.5 
Many of our patients have experienced the in-
convenience and cost of repeated monitoring, 
as well as the morbidity associated with both 
major and minor bleeding related to warfarin 
use. And there are many potential interactions 
between warfarin and foods or other drugs. 
Is the new oral anticoagulant a better bet? 
Th ere are anticoagulants that do not require 
monitoring (eg, enoxaparin), but few patients 
are willing to undergo daily subcutaneous 
injections, and the cost is often prohibitive. 
Now there is another alternative. 
Dabigatran (Pradaxa), an oral direct 
thrombin inhibitor, was approved by the 
US Food and Drug Administration in 
October 2010 for the prevention of stroke 
and systemic embolism in patients with atri-
al fi brillation.6 Dabigatran is administered 
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On average, 
patients on 
warfarin are 
within a 
therapeutic 
range only 
67% of the time. 
twice daily in a fi xed dose. Because it has a rel-
atively short half-life (12-17 hours), it does not 
require INR monitoring. Dabigatran has no 
known interactions with foods and minimal 
interactions with other medications. Its value 
as a warfarin alternative for patients with atrial 
fi brillation was addressed in the Randomized 
Evaluation of Long-Term Anticoagulation 
Th erapy (RE-LY) study detailed below.
STUDY SUMMARY
At higher dose, dabigatran prevents 
more strokes than warfarin
RE-LY included 18,113 patients from 951 fa-
cilities in 44 countries. To be eligible for the 
study, patients had to have atrial fi brillation 
documented on an electrocardiogram and at 
least one additional risk factor for stroke.
Participants were randomized into one 
of 3 groups: dabigatran 110 mg twice daily, 
dabigatran 150 mg twice daily (both admin-
istered in a blinded fashion), or warfarin 
(administered in an unblinded fashion and 
dosed to maintain an INR between 2 and 3). 
Baseline characteristics, such as age, sex, and 
CHADS2 (congestive heart failure, hyperten-
sion, age, diabetes, prior stroke) score, were 
similar across all 3 groups. Th e median dura-
tion of follow-up was 2 years, and complete 
follow-up occurred in 99.9% of participants.
Th e primary outcome of the study was 
stroke or systemic embolism. Th e primary 
safety outcome was major hemorrhage, 
defi ned as a reduction in hemoglobin of 
≥2 g/dL, transfusion of ≥2 units of blood, or 
symptomatic bleeding in a critical area/or-
gan. Other outcomes were death, myocardial 
infarction (MI), pulmonary embolism, tran-
sient ischemic attack, and hospitalization.
For the primary outcome of prevention 
of stroke or systemic embolism, the 150-mg 
dose of dabigatran was superior to warfarin 
(1.11% vs 1.69% per year, relative risk [RR], 
0.66; 95% confi dence interval [CI], 0.53-0.82; 
P<.001 for superiority). Th e major bleeding 
rates were similar for dabigatran 150 mg and 
warfarin, although major gastrointestinal 
bleeding rates were signifi cantly higher with 
this dose of dabigatran compared with war-
farin (TABLE). Minor bleeding was more com-
mon in the warfarin group (16.37% vs 14.84%; 
RR, 0.91; 95% CI, 0.85-0.97; P=.005). 
Th e 110-mg dose of dabigatran (which is 
not available in the United States) was neither 
inferior nor superior to warfarin for the pre-
vention of stroke or systemic embolism. Th is 
dose of dabigatran had a lower risk of major 
bleeding compared with warfarin. 
Mortality rates are similar
Rates of death from any cause were similar 
among the 3 treatment groups. Th e rates of 
hemorrhagic stroke were lower in both dabiga-
tran groups compared with the warfarin group, 
while rates of MI were lower in the warfarin 
group than in either of the dabigatran groups. 
Dyspepsia was the only other adverse 
eff ect that was signifi cantly more common 
among dabigatran users vs warfarin users. 
Rates of hepatotoxicity, which was a prob-
lem with earlier oral direct thrombin inhibi-
tors, were similar for both drugs. Multiple 
subgroup analyses revealed no signifi cant 
interaction between the treatment eff ect of 
dabigatran and variables such as sex, body 
mass index, creatinine clearance, CHADS2 
score, aspirin use, or previous long-term use 
of a vitamin K antagonist.
WHAT’S NEW
This easier-to-use oral anticoagulant 
is a viable option
Dabigatran gives physicians and patients 
with atrial fi brillation an option that is more 
convenient than warfarin for stroke preven-
tion. Its 150-mg dose is more eff ective in pre-
venting stroke compared with warfarin, and 
comparable in terms of bleeding risk. 
CAVEATS
Unknown long-term effects, 
potential for bias 
Th e median follow-up in the RE-LY study was 
2 years. Longer-term effi  cacy and safety data 
may diff er from the initial results. 
Th e trial was funded by Boehringer In-
gelheim, the manufacturer of dabigatran 
(Pradaxa). However, study coordination, data 
management, and analysis were performed in-
dependently by the Population Health Research 
Institute, McMaster University and Hamilton 
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Health Sciences, Hamilton, Ontario, Canada.
Patients taking dabigatran received the 
medication in a blinded fashion, but the 
warfarin group could not be blinded be-
cause of the need for INR monitoring and 
dosage adjustments. To decrease potential 
bias, the outcome events were assessed by 
2 independent investigators who were blind-
ed to the treatment assignments.
CHALLENGES TO IMPLEMENTATION
Cost of dabigatran may be a barrier 
Th e wholesale price of dabigatran, as quoted 
by Boehringer Ingelheim, is $6.75 per day; 
the retail price for a 30-day supply is approxi-
mately $235, according to drugstore.com, 
Walgreens, and Walmart). In comparison, a 
one-month supply of warfarin is about $15. 
Out-of-pocket costs for many patients will 
likely be high until dabigatran is added to 
insurers’ formularies. When costs for moni-
toring and hospitalizations or treatment for 
complications associated with warfarin are 
factored in, however, dabigatran is cost eff ec-
tive, a recent study indicates.7                 JFP
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TABLE 
Dabigatran vs warfarin: A look at the evidence1 
Incidence (%/y)
Event
Dabigatran 
(150 mg) Warfarin
NNT/NNH with 
dabigatran instead 
of warfarin Relative risk (95% CI) P value
Stroke or systemic 
embolism
1.11 1.69 NNT: 173 0.66 (0.53-0.82) <.001*
<.001
Hemorrhagic stroke 0.10 0.38 NNT: 477 0.26 (0.14-0.49) <.001
MI 0.74 0.53 NNH: 477 1.38 (1.00-1.91) .048
Death from any 
cause
3.64 4.13 NS 0.88 (0.77-1.00) .051
Major bleeding 3.11 3.36 NS 0.93 (0.81-1.07) .31
Intracranial bleeding 0.30 0.74 NNT: 228 0.40 (0.27-0.60) <.001
GI bleeding 1.51 1.02 NNH: 205 1.50 (1.19-1.89) <.001
Life-threatening 
bleeding
1.45 1.80 NNT: 286 0.81 (0.66-0.99) .04
CI, confi dence interval; GI, gastrointestinal; MI, myocardial infarction; NNH, number needed to harm; NNT, number needed to treat; NS, no signifi cant difference.
*P value for noninferiority; all other P values are for superiority.
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